Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Journal of Environmental Pathology, Toxicology and Oncology
IF: 1.241 5-Year IF: 1.349 SJR: 0.519 SNIP: 0.613 CiteScore™: 1.61

ISSN Print: 0731-8898
ISSN Online: 2162-6537

Journal of Environmental Pathology, Toxicology and Oncology

DOI: 10.1615/JEnvironPatholToxicolOncol.2017019366
pages 99-105

Regulating RNA Binding Motif 5 Gene Expression− A Novel Therapeutic Target for Lung Cancer

Venugopal Vinod Prabhu
Department of Biochemistry, University of Madras, Guindy campus, Chennai−600025, Tamil Nadu, India
Niranjali Devaraj
Department of Biochemistry, University of Madras, Guindy campus, Chennai−600025, Tamil Nadu, India

ABSTRACT

RNA-binding motif protein 5 (RBM5), also known as LUCA-15/H37, is a gene that maps to human chromosome 3p21.3, a critical region that is deleted in a large number of human cancers, of which the majority are lung cancers, and that is predicted to contain one or more tumor suppressor genes (TSGs). RBM5 is a tumor suppressor gene and is most frequently deleted at the earliest stage of lung cancer development. It represents a significant area of recent progress in cancer genomic, cytogenetic, and molecular biological research because of its role in the induction of cell cycle arrest and apoptosis and the regulation of inhibition of in lung cancer metastasis. RBM5 is involved in the suppression of epidermal growth factor receptor (EGFR) expression, thus preventing proliferation, angiogenesis, invasion, and metastasis of lung cancer. In this way it exhibits its tumor suppressive capacity during lung cancer progression. Exploration of RBM5's potential importance in inhibiting tumor metastasis includes downstream players in the RBM5-mediated metastasis suppressor pathway(s). This review highlights the differential expression of the RBM5 tumor suppressor gene which impacts cell proliferation and apoptosis control during lung cancer progression. Regulating RBM5 expression may be a novel therapeutic target for lung cancer.


Articles with similar content:

Targeting the Regulatory Machinery of BIM for Cancer Therapy
Critical Reviews™ in Eukaryotic Gene Expression, Vol.22, 2012, issue 2
Steven Grant, Hisashi Harada
Therapeutic Targeting of the Epidermal Growth Factor Receptor in Human Cancer
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 1
Nathalie S. Dhomen, Niall Tebbutt, John Mariadason, Andrew M. Scott
Role of GLI1 and NDRG1 in Increased Resistance to Apoptosis Induction
Journal of Environmental Pathology, Toxicology and Oncology, Vol.34, 2015, issue 3
William N. Rom, Yukio Hosomi, Kam-Meng Tchou-Wong, Minori Koshiji, Yiqun Mo, Feng Wu
KLF4 in Ovarian Cancer
Forum on Immunopathological Diseases and Therapeutics, Vol.7, 2016, issue 1-2
Lawrence M. Pfeffer, Baojin Wang, Ziyun Du, Junming Yue
Paracrine Sonic Hedgehog Signaling Derived from Tumor Epithelial Cells: A Key Regulator in the Pancreatic Tumor Microenvironment
Critical Reviews™ in Eukaryotic Gene Expression, Vol.22, 2012, issue 2
Xuqi Li, Erxi Wu, Hongqin Xu, Han Liu, Wanxing Duan, Qingyong Ma